<DOC>
	<DOCNO>NCT00934648</DOCNO>
	<brief_summary>This study evaluate safety efficacy MabThera patient active rheumatoid arthritis inadequate response intolerant treatment methotrexate . Eligible patient receive MabThera ( 1000mg intravenous infusion ) day 1 15 , background methotrexate ( oral subcutaneous dose 10-25mg weekly ) . After initial study period 24 week , eligible patient may receive 3 re-treatments MabThera . The anticipated time study treatment 1-2 year , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Patients With Rheumatoid Arthritis Who Have Had Inadequate Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; receive outpatient treatment ; experienced inadequate response previous current treatment methotrexate . rheumatic autoimmune disease RA , significant systemic involvement secondary RA ; history , current , inflammatory joint disease RA ; previous treatment celldepleting therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>